Here’s what you should know:
1. Takeda transferred a portion of its research business to the newly formed company.
2. Axcelead will combine Takeda’s drug discovery knowledge with its research facilities “to offer high-value drug discovery services.”
3. Axcelead will support Takeda’s group business efforts, but will also support other pharmaceutical companies, biotechnology ventures and research institutions.
More articles on improving performance:
2-level spinal fusions safe in outpatient settings, new study finds: 5 things to know
Xenco Medical launches spine system for ASCs nationally: 5 things to know
Influencing the bottom line — Dr. Allston Stubbs on diversified caseloads, growth and major specialties
